Aug 29, 2022
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Jul 31, 2022
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X Refractory NSCLC
Jul 28, 2022
Immutep Quarterly Activities Report
Jul 05, 2022
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
Jun 26, 2022
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
